Huaren Pharmaceutical Co., Ltd. (SHE:300110)

China flag China · Delayed Price · Currency is CNY
3.150
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
Market Cap3.72B -1.9%
Revenue (ttm)1.33B +6.2%
Net Income-462.97M
EPS-0.39
Shares Out1.18B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,756,520
Average Volume46,347,268
Open3.050
Previous Close3.150
Day's Range3.050 - 3.200
52-Week Range2.820 - 3.750
Beta0.42
RSI48.14
Earnings DateApr 24, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, ant... [Read more]

Sector Healthcare
Founded 1998
Employees 2,491
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300110
Full Company Profile

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.

Financial Statements